RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Upcoming ...Benedictus wrote:
MrMugsy wrote: Benedictus wrote:
MrMugsy wrote: woundedknee wrote: About time for Dan to sell some more of his shares. Christmas bills coming up. lol
Hahaha - I don't think it works that way but I could be wrong.
I think he covered some future capital gains on the sale of Antibe Holdings - but - maybe I'm wrong. I would have done that myself.
Also - I'd be more concerned about unexpected sales like the one by Wallace out of nowhere. The unknown and unexpected is a little harder to swallow. Then again, to sell at lows is more preferred than selling at highs - I respect that part of Wallace's sale.
Going forward - don't think we'll see any selling from Dan/John as we head into P2 excitement. Just my opinion.
Personally - I would have taken some of our cash and used it to buyback shares at this level - or at least threaten to do so. It would have been the absolute wrong approach with our cash ... but I would have threatened it none-the-less. : )
Mugs, I always appreciate your insights and optimism but a share buyback threat would have been an awful bluff and a tell of inept management. They need every damn penny on hand and then some...and the market knows it. I'm pleased they're just sticking to their knitting, don't need to dilute near term and moving everything forward. 2023 should be a better year for the longs and within 12 months, give or take, we will have successful acute p2 results.
I agree Benedictus ... I'm just kidding.
By the end of 2022, we'll have $42.5 MM in the bank and we need a minimum of 2 years runway.
We also need cash on hand to pay for specialists as situations call for it.
I think we spent $2 MM on Liver Specialists.
We probably spent some money figuring out the amorphous solution.
I wouldn't doubt we spent money developing a superoxide scavenger already (Antiviral ?)
We're looking at an IV form of OTENA.
Figuring out if we need 352 in a head-to-head study now.
And ... who knows what wacky and wonderful things are coming in our IBD drug.
The cash is key for development work and it keeps us in the driver seat during OTENA negotiations.
Yes and hopefully the quarterly burn rate is a little lower with acute than chronic. I appreciated Dan stressing their intention toward financial prudence. Capital is obviously extremely hard to come by nowadays. A 352 head to head comparison would be very interesting.
Yes ... the 346 and 352 head-2-head is interesting but like everything else ... it's still comes with a whole lot of confusion.
For example, I know 352 has always been Ketoprofen based.
But, I also know they're sniffing around Ketorolac for a little while.
Is this one path or is this two paths for 352 ? Don't know.
Going into 2023, there will be two IND studies as per Dan.
One is IBD.
The other is a very high painkiller (and in IV form) - assuming that's pre-op and intra-op but only guessing.
Will it be Ketorolac or Ketoprofen based ?
Then there's a woman's health opportunity - will that be Ketorolac or Ketoprofen based ?
Add to that ... the head-2-head ... and we don't know if that's for one, the other, or both.
As is always the case in drug development - we don't get details until they are patented and only then do some of the details really come out.
It's frustrating but that's just the way it's going to be in order to protect the knowledge.
Would be so much simpler if they can get the modified formulation of OTENA to do it all - would keep the costs low while increasing the overall potential.
-----------------
From a cash perspective ... aside from the cash in the bank, we can also cash up on the warrants at year-end 2023 and then again earlier in 2024 (if luck is on our side).
Smaller deals could also come through for Japan, LATAM or South-East Asia (just like China).
Add to that (on successful P2), a chance to be on the NASDAQ in late 2023 or early 2024. Less important but still a possibility. This one will not be forced but will happen as the opportunity presents itself. IMO.
I guess you could even sell one of your molecules for cash (after a successful OTENA) - but - I wouldn't advise that. Not necessary.
Just saying ... lots of ways to cash !!!!